But there is another form of exercise worth adding to the discussion: high-intensity interval training, or HIIT.

The concept is simple. Imagine you are riding an exercise bike in the gym. You pedal at a moderate pace for about 2 minutes, then you increase the resistance and pedal as fast and hard as you can for 30 seconds. You will likely sweat and your leg muscles will start to burn. You then revert to the slower, easier pace for 90 seconds and then repeat the high intensity/low intensity duo for a total of 8 rounds with a few minutes of cool down at the end. The total time elapsed is about 20 minutes and just 4 minutes of intense exercise.

My colleague Harry Oken, MD and I wrote about this interval exercise approach in our book BOOM — Boost Our Own Metabolism. At the time, one reason for our interest was evidence that intense exercise, especially early in the morning, could produce a substantial increase in human growth hormone and other metabolic responses. Another was that just a few minutes of high intensity achieved the same benefits of a much longer Zone 2 type of exercise. HIIT is a good way to maintain or increase your V02max, a known longevity positive.

There is a just published study in Cell Reports Medicine that looks much more deeply at what is happening in the body during HIIT. Led by Dr. Paul Cohen and colleagues at Rockefeller University, they found that the multiple organs, not just muscle, immediately produces many proteins that reach the blood stream and travel to other organs, call it organ cross talk.

The researchers compared two very different forms of exercise. One group cycled continuously at moderate intensity for 90 minutes. The other performed six 30-second all-out cycling sprints, separated by recovery periods as described above. Consider that this amounted to just three minutes of actual high-intensity exercise and a total of 11 minutes of total time plus the warm-up and cool-down periods.

The difference in what happened inside the body was remarkable.

The researchers measured nearly 2,900 proteins circulating in the blood. Immediately after the sprint exercise, 714, nearly one-quarter, had changed significantly, all but a few having increased substantially. Within a few hours, the protein levels had largely reverted to baseline. But in the group that did only moderate intensity cycling for 90 minutes, only seven protein levels had changed immediately.

The exerkines did not derive only from the exercised muscle, but multiple other organs including adipose, liver, immune, pancreas, intestine, and brain cells.

The researchers then went to large United Kingdom biobank databases and found that the sprint-altered proteins tended to be those connected to a reduced risk of cardiac and metabolic diseases/disorders including type 2 diabetes, obesity, and cardiovascular health. Interestingly, some of the proteins released by sprint exercise correlated with proteins in the Biobank that are associated with a decrease in biologic age.

Think about that. Three minutes of extremely vigorous exertion triggered an enormous molecular response throughout the body, but 90 minutes of moderate paced exercise did not. More importantly, those sprint derived exerkines were associated with markers of better health and a lower biologic age.

Your muscles are talking to the rest of you

We used to think about exercise largely in mechanical terms. The heart pumps faster. The lungs move more air. Muscles contract and burn fuel. Do that repeatedly and the heart and muscles become stronger. But as I have written previously, resistance exercise causes muscles (and other organs) to release chemicals (proteins, peptides, metabolites, and other signaling molecules) that travel to other parts of the body and generally have a positive effect on other organs’ cells. Instead of calling them the usual name of cytokines, meaning released by the cell, it has become customary to call them exerkines instead. By whatever name, they are metabolically active and impact the metabolism of other cells.

The Rockefeller study found evidence of communication involving muscle, fat, the liver, immune system, gastrointestinal tract, pituitary gland and even the brain. High-intensity exercise appears to send out a particularly powerful burst of these molecular messages.

Some of the proteins stimulated by intense exercise were associated, in large population databases, with lower risks of metabolic and cardiovascular disease. Others were associated with biological aging. The study does not prove that changing these proteins prevents disease or extends life, the investigators themselves are careful not to make that claim, but it offers an intriguing explanation for why relatively brief periods of vigorous exercise can produce substantial health benefits.

Instead of thinking about one hormone or one metabolic pathway, we can now begin to see intense exercise as producing a coordinated, body-wide response. Muscles do not simply become stronger. They communicate. Other organs listen and respond. That may help explain why exercise has effects seemingly far removed from the muscles doing the work.

HIIT and the aging body

This becomes especially important as we age. One of the most useful measurements of cardiovascular fitness is VO₂ max, essentially the maximum amount of oxygen the body can use during strenuous exercise. VO₂ max tends to decline with age, and a low level eventually has very practical consequences. Walking rapidly through an airport, climbing a flight of stairs, carrying groceries, or keeping up with grandchildren becomes increasingly difficult.

HIIT is particularly effective at improving VO₂ max. Studies of older adults have found that interval training can produce substantial improvements in cardiorespiratory fitness, in some studies greater than those achieved with continuous moderate exercise.

That reserve capacity matters. Independence in old age depends not merely on being able to perform today’s activities, but on maintaining enough physiological reserve to continue performing them years from now.

There may also be benefits for the brain. Exercise improves cerebral blood flow and stimulates biological pathways involved in neuroplasticity, the brain’s ability to adapt and maintain connections. Studies of HIIT in older adults have reported improvements in aspects of executive function, working memory, and attention, although the evidence is still developing. There is reason to believe that HIIT done regularly for many months reverses some of the losses of aging in the brain, both in the cortex and the hippocampus, slowing or even reversing some of the declines in normal cognitive aging and lowering the risk of dementia, but these are as yet unproven. We can say that maintaining cardiovascular fitness and remaining physically active are important components of maintaining brain health.

But HIIT does not mean sprinting

Here an important caution is necessary, especially for older adults.

The Rockefeller participants performing six all-out sprints were young, healthy adults. I certainly would not recommend that an 80-year-old who has been sedentary climb onto a bicycle tomorrow and attempt six or eight maximal 30-second sprints.

“High intensity” is relative. Someone who has been sedentary or who has cardiovascular, pulmonary, or significant muscle loss should discuss vigorous exercise with their physician, and if approved, begin under the guidance of a personal trainer or physical therapist. The objective is not exhaustion. It is to periodically ask the cardiovascular and metabolic systems to work substantially harder than they do during ordinary activity, followed by recovery.

Don’t give up your walk or your weights

HIIT should not replace other exercises. Continue walking. Continue cycling, swimming or whatever aerobic activity you enjoy. And especially as you grow older, include resistance exercise at least twice a week. Muscle mass and strength are essential for getting out of a chair, climbing stairs, maintaining balance, and preventing frailty. These are the essential elements of retaining independence.

Think of high-intensity intervals as an addition, a very useful addition. Once or twice a week, if your health permits and your doctor agrees, consider adding a few brief periods during your usual aerobic exercise when you substantially increase the intensity and then recover. As fitness improves, the duration or number of intervals can gradually increase.

The remarkable message from the Rockefeller study is that our bodies notice the difference.

Three minutes of intense exertion caused hundreds of proteins and metabolites to change, initiating communication among organs throughout the body. We are only beginning to understand what all those molecular conversations mean. But they reinforce something we already know. Exercise is among the most powerful medicines available to us. As we age, the goal is not to become an athlete. The goal is to preserve enough strength, cardiovascular capacity, balance, and brain function to continue doing the things that make life enjoyable. And most importantly, it is to maintain independence.

Walking matters. Strength training matters. And now we have a reason to pick up the pace.

It suggests to me, and as Dr Oken I wrote in BOOM — Boost Our Own Metabolism, a regular program of HIIT, once or twice a week for just 20 minutes, is beneficial to our health. At age 84, I plan to redouble my efforts to do it at least once a week, maybe two.

It is never too late to start and sometimes it pays to go a little faster.

The post A Few Minutes of Intense Exercise Can Change Your Body appeared first on Medika Life.

This is the world that reproductive psychiatry tries to fix. It is the branch of medicine that treats mental health problems tied to pregnancy, childbirth, and the months after birth. It covers depression, severe anxiety, panic attacks, obsessive thoughts about the baby’s safety, bipolar disorder, and the rare but severe break from reality called postpartum psychosis.

Roughly one in five pregnant and postpartum women deal with some kind of mental health condition, from anxiety to depression to more severe illness. Yet only about one in four women with postpartum depression symptoms ever gets a diagnosis, and about half of those get no treatment at all.

For years, physicians and hospitals focused mostly on physical dangers like blood loss during birth. Nurses were trained to watch a mother’s blood pressure, bleeding, and vital signs, but not always her mood, sleep, or thoughts. The numbers now tell a different story, and it is not a comfortable one.

A Killer Hiding in Plain Sight

Federal health reviewers looked closely at deaths connected to pregnancy across dozens of states. Mental health conditions, including suicide and drug overdose, caused close to a quarter of those deaths. Suicide alone accounted for nearly a third of the mental health-related deaths in the most recent review.

A separate large study presented to maternal health doctors went even further. It found that homicide and suicide combined were the single leading cause of death among pregnant and postpartum women, ahead of every physical complication doctors traditionally worry about, including bleeding and high blood pressure.

The danger is not shared equally. Black mothers between the ages of eighteen and twenty-four die from violence during pregnancy and the months after birth at nearly four times the national rate. Researchers also found that states with stronger gun laws saw meaningfully fewer of these violent deaths, suggesting that policy choices outside the hospital walls still shape what happens inside it.

Most of these deaths did not have to happen. Review boards that study them in detail found that the overwhelming majority were preventable, with earlier warning, better screening, or faster access to care. That finding sits at the center of why reproductive psychiatry matters. It is not a small corner of medicine. It is a matter of life and death for young families, and it has been treated as an afterthought for far too long.

When the Warning Signs Are Missed

One of the most frightening conditions in this field is postpartum psychosis. It is rare, striking roughly one or two mothers out of every thousand births, but it can move fast and turn deadly within days. A woman can go from mild sleep trouble to hearing voices or believing things that are not true in hours.

Studies show that a meaningful share of mothers with untreated postpartum psychosis will attempt suicide, and a smaller number will harm their child. Physicians and advocates who work in this space are clear about one thing. Postpartum psychosis is a medical emergency, and with fast, proper treatment, most mothers recover fully.

This condition drew national attention when a Massachusetts nurse named Lindsay Clancy went on trial after the deaths of her three young children. Her attorneys argued that severe, untreated postpartum psychosis, not any intent to harm, drove her actions that day. The trial ended without a verdict after jurors could not agree on whether she was criminally responsible. One juror held out in the case. The defense attorney has requested an investigation into his actions.

Physicians who study the condition say cases like hers expose a hard truth. There is no standard screening test for postpartum psychosis, the way there is for postpartum depression, so doctors and family members are often left guessing until symptoms become severe.

Warning signs can include not sleeping for several nights in a row, racing or jumbled thoughts, sudden confusion about what is real, and strange new beliefs about the baby. Legal experts add that courts rarely weigh a mother’s mental state fairly. Only one state currently allows undiagnosed or untreated postpartum psychosis to count in a mother’s favor during sentencing. The gap between what medicine knows about this illness and what the legal system recognizes remains wide. How do you find someone guilty of murder when the research is so limited and faulty, and the treatment is almost pure guesswork?

Confusion at the Pharmacy Counter

Reproductive psychiatry is also fighting a newer problem, public confusion over which medications are actually safe. In September 2025, federal health officials warned that Tylenol use during pregnancy might raise a child’s risk of autism, based on studies that many scientists consider far from settled. In the months that followed, emergency rooms saw pain medication orders for pregnant patients drop by about ten percent, even as new large studies kept finding no clear link between Tylenol and autism.

Antidepressants came under a similar kind of pressure. A federal advisory panel questioned the safety of these drugs during pregnancy, and several panel members claimed, without solid evidence, that the medications cause autism or do not work at all. Leading reproductive psychiatrists pushed back hard.

One new study tracked thousands of patients who had been taking antidepressants for depression or anxiety before becoming pregnant. Those who stopped their medication during pregnancy needed emergency mental health care far more often than those who stayed on it. Untreated depression on its own raises the risk of early birth and dangerous high blood pressure during pregnancy. Doctors in the field say there is no convincing evidence that antidepressants cause autism or birth defects.

This kind of public confusion often pushes women toward the riskier choice, going without needed treatment, out of fear of a smaller and far less certain risk. On top of the confusion, there simply aren’t enough specialists. It’s the same in geriatrics, where few specialists are available.

Many towns and even entire regions have no reproductive psychiatrist at all. To close that gap, hospitals and universities have started programs that let a family doctor or an obstetrician call a psychiatric expert for guidance on the spot, rather than sending every patient to a specialist who might be hours away. These access programs are growing, but they still reach only a fraction of the mothers who need them.

Reproductive psychiatry sits at a hard crossroads. The evidence is clear that mental health, not bleeding or high blood pressure, is now the greatest threat to mothers in the weeks surrounding childbirth. Yet screening tools remain incomplete, public trust has been shaken by conflicting claims from officials, and specialists are spread thin across a country where many families live far from real help.

The good news is that nearly everything described here responds to treatment. Depression and anxiety improve with therapy and medication. Even postpartum psychosis, as frightening as it is, gets better with fast psychiatric care. The real danger is rarely the illness itself. Silence, delay, and bad information often stand between a mother and the help she needs.

Family members often notice first that something is wrong. Physicians in this field give the same advice again and again. Do not wait. Do not assume the feeling will simply pass. And do not let fear over a medication rumor stand between a mother and the treatment that could save her life. A mother’s mental health is not a footnote to her physical recovery from childbirth. It is central to whether she and her baby come through this season of life safely.

The post When Having a Baby Becomes a Mental Health Emergency appeared first on Medika Life.

I told her it was more complicated.

A few days later, I read a study about hormone therapy and dementia. Researchers followed more than 180,000 postmenopausal women for an average of 13 years. Women who had used hormone therapy for at least a year had a lower risk of developing dementia. The association was strongest among women who started between ages 46 and 56.

In 2003, researchers from the Women’s Health Initiative Memory Study reported that women taking estrogen plus progestin had about twice the risk of probable dementia. It was a randomized trial. But the women in that trial were 65 or older. That detail got smaller somewhere between the medical journals and the doctors’ offices, smaller still by the time it reached how women understood their own bodies. The warning traveled farther than the population it actually studied.

Hormone therapy became something to fear. I watched it happen. Women became wary. Physicians became reluctant to prescribe it. A decision that should have turned on age, symptom severity, type of hormone, and individual risk became a simple rule: dangerous.

My patient’s question wasn’t really about dementia studies. Her cancer had forced her backward through her own medical history, and now that history was being reexamined through the lens of a terrible outcome. Medical warnings move out of journals into people’s lives. They attach to regret. They become the story people tell about their own choices.

The new study doesn’t erase the old one. Put them together and something becomes visible: one studied women 65 and older, the other found its strongest association with lower dementia risk among women starting between 46 and 56. The warning was built on a population that looks very different from the population now receiving it.

A third study adds to this. Researchers examining autopsied brains found less Alzheimer pathology among women who had used estrogen-only hormone therapy. We don’t know if this means anything — autopsy studies can’t prove what prevented anything. But neither can we keep treating a single finding from a 2003 trial of older women as though it applies equally to a 50-year-old having hot flashes every two hours, whose brain fog has made her work nearly impossible.

The question was never whether hormones are good or bad. It was which ones, for whom, at what age, for what.

If a woman sat across from me now considering hormone therapy, I would want to know what was happening in her life before we talked about treatment. Is she waking in hot flashes? Has her concentration fractured? Is anxiety moving through her day? What is her medical history and what does she carry into this decision? What does she want treatment to actually do?

These questions don’t become headlines. They’re closer to medicine.

My patient last week was frightened about cancer, not dementia. But underneath her question was what I hear whenever someone is trying to make sense of something terrible: Did I make the wrong choice? The woman in the 2003 trial was 65 years old. My patient made her decision at 50. But that warning didn’t stay in the journal. It moved out into the world and landed on every woman, at every age, in every stage of this transition, saying the same thing: don’t do this, it will damage you.

If you’re navigating menopause and trying to make sense of what’s changing and what actually deserves treatment, I wrote The Menopause Guide to help with exactly that — understanding the changes, sorting through your options, and preparing for a conversation with your clinician that’s grounded in what you actually need, not what you’re afraid of.

Get The Menopause Guide

The post Did We Get Hormone Therapy Wrong? appeared first on Medika Life.

Women never experience their health that way. Their lives do not fit neatly into funding categories, medical specialties or isolated episodes of care. Health is a continuum that shifts over time, and the market is finally beginning to recognize its size, scientific potential, and human importance.

A new W Group study, “The Road to the Era of Scale,” provides compelling evidence of that shift. Based on the organization’s tracking of more than 500 funding stories and approximately 164 disclosed equity rounds across 15 categories and more than 30 countries, the report found that women’s health companies raised a record $1.55 billion in disclosed equity in 2025, a 41% increase from 2024.

A Market Is Forming, Not Merely Making Headlines

Investment totals can be deceptive. One enormous financing round can make an entire sector appear stronger, deeper, and more expansive than it is in reality. The significance of the W Group findings is that the capital did not simply increase. It spread over the continuum of women’s health.

Eighty-five women’s health companies raised equity in 2025, the highest annual number in the report’s data. Ten rounds reached at least $50 million, twice as many as in 2024, and the average disclosed round grew 29%, from approximately $13.9 million to $18 million.

Capital also became less concentrated among a few celebrated companies. The three largest rounds represented 39% of disclosed funding in 2024, compared with 32% in 2025. Funding received by companies outside the top three grew by 56%, a potential signal that investors are beginning to support a broader range of clinical needs, technologies and business models.

This is what the development of an investment ecosystem looks like. Capital begins to flow beyond the familiar names and into diagnostics, therapeutics, clinical infrastructure and care models that address different stages of a woman’s life.

Oncology received the largest share of investment, with the report estimating more than $600 million across at least 12 rounds. Fertility and assisted reproductive technology attracted more than $230 million, while maternal health drew approximately $160 million. Menopause, sexual and reproductive health, hormone diagnostics and pelvic health also received new support.

Endometriosis offers a particularly important example. Long dismissed, misunderstood and frequently diagnosed only after years of pain, the condition attracted more than $56 million across five rounds in 2025. The investments spanned therapeutics, diagnostics, and imaging, suggesting that the market is beginning to view endometriosis as a complex clinical challenge requiring multiple forms of innovation.

The same shift can be seen in metabolic health. SheMed’s $50 million Series A helped establish women-specific GLP-1 care as an investable category, reflecting the growing recognition that medicines, monitoring and health interventions must account for biological differences rather than treating the male body as the universal clinical norm.

The Women’s Health Innovation Map Is Becoming Global

The United States remains the dominant destination for women’s health capital, but the sector is no longer exclusively an American story. The US ecosystem also benefits from Organon, one of the few global pharmaceutical companies built around women’s health, whose portfolio, partnerships and commercial reach can help promising science cross the difficult divide between startup innovation and patient access.

Beyond the United States, the report found a broader geographic footprint in 2025, with companies and investors across Europe, Israel, India, Canada and the Middle East contributing to the market’s development.

The UK was the most active non-US ecosystem by company count in the W Group data. British companies were represented across metabolic health, endometriosis, hormone diagnostics, menstrual health, maternal care and other categories.

That entrepreneurial activity is now being matched by policy attention. England published a renewed 10-year Women’s Health Strategy in April 2026, aligned with the country’s broader health plan and centered on giving women greater voice, choice and power in decisions about their care. The government has also outlined efforts to streamline gynecologic care, improve access for conditions such as endometriosis and fibroids and confront inadequate approaches to women’s pain.

This matters because innovation cannot succeed through capital alone. A company may develop a better diagnostic or care platform. Still, its impact will remain limited unless clinicians trust it, health systems can adopt it, reimbursement supports it and patients can reach it. That is the difference between invention and innovation.

France is building another part of that infrastructure. The Île-de-France region has created FemTech Île-de-France, an investment fund targeting €50 million for women’s health innovation, supported by the scientific expertise of Université Paris Cité. Regional plans also include a specialized incubator effort and an interdisciplinary institute that connects research, clinical education, and innovation.

The French initiative is notable because it does not treat funding as an isolated intervention. It attempts to link capital with scientific expertise, company development and a regional health innovation strategy. That combination can help promising startups move beyond an initial idea and toward evidence, regulatory progress and clinical adoption.

France’s women’s health momentum is also reflected in Lyon-based Ziwig Biotech, whose Endotest uses salivary RNA analysis and artificial intelligence to provide a noninvasive diagnostic test for endometriosis, demonstrating how French biotechnology can turn a condition long marked by diagnostic delay into a precision-medicine opportunity.

Israel contributes another important dimension. Its health innovation culture is built upon deep scientific expertise, sophisticated health data, globally connected medical centers and an instinct for solving difficult clinical problems. In 2025, Israel presented a delegation of women’s health innovators at Expo 2025 Osaka, bringing companies and health leaders together with counterparts from Japan, the United States and Mexico.

Israel’s strength in technology, however, coexists with a persistent capital and leadership gap for women. An Israel Innovation Authority report found that women remain approximately one-third of the country’s high-tech workforce, while holding only 17% of senior management positions and 10% of startup CEO roles. The number of women working in research and development has risen sharply, but their representation in entrepreneurship, leadership and investment remains disproportionately low.

That disparity should concern anyone interested in women’s health innovation. When women are missing from the rooms where companies are founded, clinical priorities are established and capital is allocated, unmet needs are more likely to remain unseen.

The opportunity in Israel has two paths to consider. The country can export women’s health technologies to global markets while also ensuring that more women participate as founders, scientific leaders, investors and decision-makers shaping those innovations.

The Most Dangerous Gap Sits in the Middle

The report’s most urgent finding is not the record amount invested. It is the continuing Series A bottleneck.

Approximately 35-40 women’s health companies raised seed or pre-seed capital in each of the two years studied. Only about 20 to 25 reached Series A, and many companies that appeared at the seed stage in 2024 did not return with a Series A round in 2025.

Seed funding can demonstrate that a concept is interesting. Series A funding is often the stage at which a company must demonstrate that the concept can become clinically credible, commercially sustainable, and capable of operating within a complex health system.

This stage requires companies to generate evidence, recruit specialized talent, navigate regulation, protect sensitive patient information and establish a credible path to payment. It is also where founders discover that a technically elegant solution may not fit naturally into clinical workflows or address the daily realities faced by patients and health professionals.

The loss of promising companies at this stage is not only a financial concern. A stalled financing round can mean that an earlier diagnostic never reaches a physician, a new treatment never enters a clinical trial or a more humane care model never reaches the people who need it.

Specialist funds can help bridge that gap, and the report identified at least 11 new investment vehicles launched in 2025 with a women’s health mandate. Pharmaceutical companies and major generalist venture firms are also beginning to participate, an important sign that the sector is moving beyond support from a small circle of committed specialists.

The transition remains incomplete. Women’s health will not achieve sustained growth until generalist investors consider it a standard component of health investing rather than a special theme to be visited only occasionally.

Capital Still Follows Visibility More Than Burden

The funding pattern also reveals an uncomfortable truth. Conditions receiving the most investment are not always those creating the greatest health burden.

The report estimates that women-specific cardiovascular innovation received only about $2 million in dedicated equity during 2025. Dedicated investment addressing the women-specific dimensions of autoimmune disease was effectively absent, even though women account for the great majority of people living with autoimmune conditions. Mental health and pelvic health also remained dramatically underfunded in relation to their effects on people’s lives.

This does not diminish the importance of investment in fertility, oncology, menopause or maternal health. It does show that markets often follow categories that are easier to describe, sell or recognize before addressing conditions that are scientifically complex, poorly diagnosed or fragmented across medical specialties.

Cardiovascular disease in women is not a niche concern. Autoimmune disease is not a specialty-market curiosity. These are major health challenges that demand gender-specific research, earlier diagnosis, appropriate clinical evidence and investors prepared to build a long-term thesis.

Five years ago, menopause appeared similarly overlooked. Greater visibility, advocacy and scientific attention helped change investor understanding. Cardiovascular, autoimmune, and mental health innovation now requires a comparable shift.

Scale Must Mean Better Health Access, Not Only Larger Rounds

Investment is essential, but capital is not the same as care. A successful financing announcement does not reduce the years a woman may wait for an endometriosis diagnosis, reduce the risk of maternal complications or ensure that a new technology reaches people regardless of income or geography.

The true value of capital lies in what it enables people to create. It can help researchers produce evidence, enable founders to recruit skilled R&D teams and give companies time to earn the confidence of regulators, health professionals, payers and patients.

Technology should simplify care rather than introduce another point of friction. Data should help clinicians understand women more fully rather than reproduce historical bias. Artificial intelligence, or its application, should enhance human judgment, not serve as an excuse for health professionals to distance themselves from the people they serve.

The women’s health sector no longer needs to prove that unmet need exists. The record of delayed diagnoses, inadequate research, and dismissed symptoms has been established many times over.

It also no longer needs to prove that successful companies can be created. The expansion of investment across more categories, countries and later-stage rounds shows that women’s health can produce significant scientific advances and scalable enterprises.

The question now is whether investors, policymakers and health systems will support those companies through the winding journey from possibility to practice. That will require patient capital, stronger evidence, workable reimbursement pathways, and a willingness to design care around women’s lives rather than forcing women to navigate systems not designed with them in mind.

The W Group Era of Scale analysis should not be measured only by how much capital enters women’s health. It should be measured by whether that investment leads to earlier diagnoses, better treatments, broader access and less suffering. The true measure of scale will not be dollars invested, but lives improved.

The post Women’s Health Has Entered the Era of Scale. Now Capital Must Catch Up With Care appeared first on Medika Life.